Mohamed M. Swidan

Dr. Mohamed M. Swidan


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
TSTamer Sakr
Tamer Sakr
OKO.M. Khowessah
O.M. Khowessah
MMM.A. Motaleb
M.A. Motaleb
AEA. Abd El-Bary
A. Abd El-Bary
MEM.T. El-Kolaly
M.T. El-Kolaly
MSMohamed M. Swidan
Mohamed M. Swidan

1 August 2014 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
MSMohamed M. Swidan
Mohamed M. Swidan
TSTamer Sakr
Tamer Sakr
MMM. A. Motaleb
M. A. Motaleb
AEA. Abd El‐Bary
A. Abd El‐Bary
MEM. T. El‐Kolaly
M. T. El‐Kolaly

31 January 2019 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
MSMohamed M. Swidan
Mohamed M. Swidan
OKOmnya M. Khowessah
Omnya M. Khowessah
MEMohamed Abd El-Motaleb
Mohamed Abd El-Motaleb
AEAhmed Abd El-Bary
Ahmed Abd El-Bary
MEMohamed T. El-Kolaly
Mohamed T. El-Kolaly
TSTamer Sakr
Tamer Sakr

19 July 2014 in Journal of Radioanalytical and Nuclear Chemistry
Verified
Journal Article
Closed access
PDF file
MSMohamed M. Swidan
Mohamed M. Swidan
TSTamer Sakr
Tamer Sakr
MMM. A. Motaleb
M. A. Motaleb
AEA. Abd El-Bary
A. Abd El-Bary
MEM. T. El-Kolaly
M. T. El-Kolaly

12 June 2024 in Cancer Nanotechnology
Verified
Journal Article
Open access
PDF file
MSMohamed M. Swidan
Mohamed M. Swidan
NWNehal S. Wahba
Nehal S. Wahba
TSTamer M. Sakr
Tamer M. Sakr
Background: Recent advances in clinical transformation research have focused on chemodynamic theranostics as an emerging strategy for tackling cancer. Nevertheless, its effectiveness is hampered by the tumor's glutathione antioxidant effect, poor acidic tumor microenvironment (TME) and inadequate endogenous H2O2. Hence, we designed an activatable theranostics (99mTc-DOX loaded AA-Fe3O4@FeIII-TA) that effectively boost the catalytic efficiency of the Fenton-reaction-induced ROS production and augment the chemotherapeutic efficacy combined with diagnostic action. Results: A cross-linked matrix of tannic acid-ferric salt (FeIII-TA) as a pH-responsive shell onto ascorbic acid-decorated iron-oxide nanoparticles (AA-Fe3O4NPs) was prepared demonstrating a metal–organic- framework (MOF) nanostructure, followed by loading of 99mTc-labelled DOX. The platform (99mTc-DOX loaded AA-Fe3O4@FeIII-TA) displayed suitable physical–chemical properties, including 69.8 nm particle size, 94.8 nm hydrodynamic size, − 21 mV zeta potential, effective FeIII-TA shell crosslinking onto AA-Fe3O4NPs and 94% loading efficiency for 99mTc-DOX. The results of the in-vitro release investigations showed that the platform exhibited a pH-dependent release manner with 98.3% of the 99mTc-DOX being released at pH 5 (simulating the tumor’s pH) and only 10% being released at the physiological pH (pH 7.4). This indicates that there was negligible payload leakage into the systemic circulation during the platform's passive accumulation inside tumor. Due to the acidic TME nature, the MOF shell might be degraded releasing free FeIII, TA and a sustained release of 99mTc-DOX. Besides its chemotherapeutic impact and capacity to raise intracellular H2O2 content, the released 99mTc-DOX might be used as SPECT imaging tracer for concurrent tumor diagnosis. Furthermore, the mild acidity of the tumor may be overcome by the released TA, which might raise the acidification level of cancer cells. The released FeIII, TA and the endogenous GSH could engage in a redox reaction that depletes GSH and reduces FeIII to FeII ions which subsequently catalyze the elevated concentration of H2O2 to reactive •OH via Fenton-like reaction, increasing the effectiveness of chemodynamic therapy. Moreover, the in-vivo evaluation in tumor-bearing mice showed significant radioactivity accumulation in the tumor lesion (16.8%ID/g at 1 h post-injection) with a potential target/non-target ratio of 8. Conclusions: The 99mTc-DOX loaded AA-Fe3O4@FeIII-TA could be introduced as an effective chemo/chemodynamic theranostics. Graphical

7 June 2024 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
MSMohamed M. Swidan
Mohamed M. Swidan
FMFawzy Marzook
Fawzy Marzook
TSTamer M. Sakr
Tamer M. Sakr
Despite enormous advancements in its management, cancer is the world's primary cause of mortality. Therefore, tremendous strides were made to produce intelligent theranostics with mitigated side effects and improved specificity and efficiency. Thus, we developed a pH-sensitive theranostic platform composed of dextran immobilized zinc oxide nanoparticles, loaded with doxorubicin and radiolabeled with the technetium-99m radionuclide (99mTc-labelled DOX-loaded ZnO@dextran). The platform measured 11.5 nm in diameter with −12 mV zeta potential, 88% DOX loading efficiency and 98.5% radiolabeling efficiency. It showed DOX release in a pH-responsive manner, releasing 93.1% cumulatively at pH 5 but just 7% at pH 7.4. It showed improved intracellular uptake, which resulted in a high growth suppressive effect against MCF-7 cancer cells as compared to the free DOX. It boasted a 4 times lower IC50 than DOX, indicating its significant anti-proliferative potential (0.14 and 0.55 μg ml−1, respectively). The in vitro biological evaluation revealed that its molecular mode of anti-proliferative action included downregulating Cdk-2, which provoked G1/S cell cycle arrest, and upregulating both the intracellular ROS level and caspase-3, which induced apoptosis and necrosis. The in vivo experiments in Ehrlich-ascites carcinoma bearing mice demonstrated that DOX-loaded ZnO@dextran showed a considerable 4-fold increase in anti-tumor efficacy compared to DOX. Moreover, by utilizing the diagnostic radionuclide (99mTc), the radiolabeled platform (99mTc-labelled DOX-loaded ZnO@dextran) was in vivo monitored in tumor-bearing mice, revealing high tumor accumulation (14% ID g−1 at 1 h p.i.) and reduced uptake in non-target organs with a 17.5 T/NT ratio at 1 h p.i. Hence, 99mTc-labelled DOX-loaded ZnO@dextran could be recommended as a rectified tumor-targeted theranostic platform.